Bruker/$BRKR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bruker
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Ticker
$BRKR
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
11,396
ISIN
US1167941087
Website
Bruker Metrics
BasicAdvanced
$6.4B
80.35
$0.52
1.16
$0.15
0.47%
Price and volume
Market cap
$6.4B
Beta
1.16
52-week high
$70.58
52-week low
$34.10
Average daily volume
2.1M
Dividend rate
$0.15
Financial strength
Current ratio
1.57
Quick ratio
0.665
Long term debt to equity
113.181
Total debt to equity
114.185
Dividend payout ratio (TTM)
38.44%
Interest coverage (TTM)
7.15%
Profitability
EBITDA (TTM)
599.8
Gross margin (TTM)
49.90%
Net profit margin (TTM)
2.31%
Operating margin (TTM)
11.62%
Effective tax rate (TTM)
50.53%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
4.88%
Return on equity (TTM)
4.76%
Valuation
Price to earnings (TTM)
80.354
Price to revenue (TTM)
1.843
Price to book
3.49
Price to tangible book (TTM)
-4.92
Price to free cash flow (TTM)
36.382
Free cash flow yield (TTM)
2.75%
Free cash flow per share (TTM)
115.94%
Dividend yield (TTM)
0.36%
Forward dividend yield
0.47%
Growth
Revenue change (TTM)
14.84%
Earnings per share change (TTM)
-80.80%
3-year revenue growth (CAGR)
11.92%
10-year revenue growth (CAGR)
7.08%
3-year earnings per share growth (CAGR)
-34.30%
10-year earnings per share growth (CAGR)
5.08%
3-year dividend per share growth (CAGR)
5.57%
What the Analysts think about Bruker
Analyst ratings (Buy, Hold, Sell) for Bruker stock.
Bulls say / Bears say
Bruker's preliminary Q4 2024 revenue exceeded expectations, indicating strong performance and potential for continued growth. (Investing.com)
The company's launch of the X4 POSEIDON™ advanced X-ray microscope positions it at the forefront of 3D microscopy, potentially driving future sales. (StockInvest.us)
Bruker's strategic acquisitions, including Nanostring, are expected to enhance its market position and contribute to revenue growth. (Investing.com)
Analysts have reduced Bruker's Q1 2025 earnings estimates, reflecting concerns about potential underperformance. (MarketBeat)
The company lowered its FY2024 guidance due to delays in biopharma and China market recoveries, indicating potential revenue challenges. (Benzinga)
Bruker's adjusted EPS for Q1 2025 declined by 11.3% year-over-year, suggesting margin pressures that could impact profitability. (TradingView News)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
Bruker Financial Performance
Revenues and expenses
Bruker Earnings Performance
Company profitability
Bruker News
AllArticlesVideos
Bruker Experiences Growth in Semiconductor Advanced Packaging Market Fueled by AI Demands
Business Wire·4 days ago
Bruker Applied MS Unveils Strategic Innovations at ASMS 2025, Showcasing Advances in DART Technology for TDM and DoA Analysis and Launching timsMetabo™ for PFAS and Environmental Contaminant Detection
Business Wire·4 weeks ago
Bruker Unveils New proteoElute™ nanoLC System and PepSep® Advanced nLC Columns for up to 50% Improved Peptide Sensitivity
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bruker stock?
Bruker (BRKR) has a market cap of $6.4B as of June 28, 2025.
What is the P/E ratio for Bruker stock?
The price to earnings (P/E) ratio for Bruker (BRKR) stock is 80.35 as of June 28, 2025.
Does Bruker stock pay dividends?
Yes, the Bruker (BRKR) stock pays dividends to shareholders. As of June 28, 2025, the dividend rate is $0.15 and the yield is 0.47%. Bruker has a payout ratio of 38.44% on a trailing twelve-month basis.
When is the next Bruker dividend payment date?
The next Bruker (BRKR) dividend payment date is unconfirmed.
What is the beta indicator for Bruker?
Bruker (BRKR) has a beta rating of 1.16. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.